Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB) from its SEC filings: 2025 revenue $62.9 million (+699% vs the year before), net margin -325%, free cash flow -$173.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $62.9 million |
| Revenue growth | +699% |
| Net income | -$204.6 million |
| Net margin | -325.3% |
| Free cash flow | -$173.4 million |
| Diluted EPS | $-0.60 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +556% |
| Cash | $258.6 million |
| Long-term debt | $242.6 million |
| Share count, 1 year | +3% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.